Zydus Wellness reported a consolidated net profit of ₹1,189 million for the quarter ended June 30, 2026 (Q1FY26), down from ₹1,279 million in the same period last year. Despite this decline in bottom-line profitability, the company’s top line expanded significantly, with revenue from operations rising 67% year-on-year to ₹14,370 million from ₹8,609 million. The divergence between revenue growth and profit contraction was driven by increased operational costs, particularly in advertisement and promotion, which expanded the cost base faster than earnings could absorb it following recent strategic acquisitions.

Q1FY26 Financial Performance

The Board of Directors approved the unaudited financial results on August 4, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and limited reviewed by Mukesh M. Shah & Co., the statutory auditors. The trading window under SEBI (Prohibition of Insider Trading) Regulations, 2015 remained closed until August 6, 2026, reopening for directors and designated persons on August 7, 2026.

Revenue growth was primarily fueled by the inclusion of Comfort Click Limited (CCL), acquired by subsidiary Alidac UK Limited in August 2025, and the consolidation of Naturell (India) Private Limited (NIPL) business effective September 20, 2025. However, total expenses rose sharply to ₹12,787 million from ₹7,186 million. Advertisement and promotion expenses more than doubled to ₹2,612 million from ₹1,325 million, while other expenses jumped to ₹3,435 million from ₹1,171 million. Consequently, while absolute EBITDA expanded to ₹2,420 million from ₹1,560 million, the EBITDA margin contracted to 16.82% from 18.10%.

Key Operational Developments

The company operates in a single segment: "Consumer Products." The acquisition of CCL by Alidac UK Limited for GBP 239 million plus a profit-ticker payment of GBP 2.64 million has significantly expanded the group's international footprint. The financial results include CCL's operations from August 29, 2025, based on provisional purchase price allocation figures. Additionally, the voluntary liquidation of NIPL was completed, with its business undertaking distributed to Zydus Wellness on a going concern basis, consolidating its operations from September 20, 2025.

Tax and Exceptional Items

Total tax expense increased to ₹432 million from ₹174 million in Q1FY25. This includes a reversal of Minimum Alternate Tax (MAT) credit entitlement of Nil for Q1FY26, compared to ₹146 million in the prior year period. There were no exceptional items in Q1FY26. In contrast, FY25 saw exceptional expenses related to NIPL liquidation and CCL acquisition totaling ₹408 million, which included costs associated with the new Labour Codes.

Standalone Results

On a standalone basis, Zydus Wellness posted a net profit of ₹55 million for Q1FY26, up from ₹46 million in Q1FY25. Standalone revenue from operations was ₹1,530 million, compared to ₹1,409 million in the previous year. The standalone profit before tax stood at ₹74 million, slightly lower than ₹79 million in Q1FY25. The company had previously approved the split of equity shares from a face value of ₹10 to ₹2 each, which was effected on September 19, 2025.

Zydus Wellness has indicated that it expects growth to resume for two of its prominent brands — Nycil and Glucon-D — as the company looks ahead to the upcoming season with an optimistic stance.

Positive Seasonal Outlook for Key Brands

The company has highlighted a constructive outlook for the coming season, underpinned by the absence of inventory-related issues that had previously posed challenges. Zydus Wellness noted that without the overhang of inventory problems, both Nycil and Glucon-D are well-positioned to return to a growth trajectory.

Brand Overview

Nycil and Glucon-D are among the flagship consumer health and wellness brands in the Zydus Wellness portfolio. The following table summarizes the key developments highlighted by the company:

The company's commentary reflects confidence in the demand environment for these seasonal products, with inventory levels described as being in a healthy position ahead of the peak consumption period.

Key Highlights

• Growth resumption expected for both Nycil and Glucon-D
• Positive seasonal outlook cited by the company
• No inventory challenges anticipated for the upcoming season
• Management confidence in the demand trajectory for these key brands

Zydus Wellness's forward-looking commentary on Nycil and Glucon-D underscores the company's focus on driving performance across its core consumer health portfolio as seasonal demand picks up.